Tarsus Pharmaceuticals’ (TARS) Buy Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS) in a report released on Monday morning,Benzinga reports.

A number of other equities analysts have also commented on TARS. Oppenheimer raised their price target on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Barclays lifted their price objective on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. Finally, The Goldman Sachs Group raised their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $56.00.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ TARS opened at $52.33 on Monday. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The stock’s 50 day moving average price is $52.06 and its 200-day moving average price is $41.30. The company has a market capitalization of $2.00 billion, a PE ratio of -13.73 and a beta of 1.01.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC raised its holdings in Tarsus Pharmaceuticals by 16.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock worth $6,924,000 after acquiring an additional 29,465 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Tarsus Pharmaceuticals by 2,088.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after purchasing an additional 420,057 shares during the last quarter. Creative Planning bought a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at about $362,000. Vestal Point Capital LP bought a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at about $7,565,000. Finally, Jennison Associates LLC raised its position in shares of Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after buying an additional 321,552 shares in the last quarter. 90.01% of the stock is owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.